04.10.2016 Evotec AG  DE0005664809

DGAP-News: EVOTEC AND CARRICK THERAPEUTICS BUILD STRATEGIC ALLIANCE


 
DGAP-News: Evotec AG / Key word(s): Alliance EVOTEC AND CARRICK THERAPEUTICS BUILD STRATEGIC ALLIANCE 04.10.2016 / 07:29 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- - Evotec contributes $ 6 m to Carrick's $ 95 m funding round through a top-class global investor consortium - Carrick Therapeutics ("Carrick") and Evotec build discovery alliance for novel oncology targets Hamburg, Germany, 04 October 2016: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that in line with its strategy to participate in promising corporate formations it will deepen its already existing relationship with Carrick. Evotec will invest up to $ 6 m towards Carrick's latest funding round. The total $ 95 m round was led by ARCH Venture Partners and Woodford Investment Management with participation from Cambridge Enterprise Seed Funds, Cambridge Innovation Capital, Google Ventures (GV), Lightstone Ventures, and Evotec AG. Carrick, headquartered in Dublin with R&D located in Oxford and Dublin has a clear vision for cancer patients: Its mission is to target the molecular pathways that drive the most aggressive and resistant forms of cancer in order to have a major impact on the lives of patients. Instead of banking on a single compound or biological mechanism, Carrick is building an innovative portfolio of first-in-class treatments that target multiple mechanisms of the most aggressive forms of cancer, and which will be tailored to an individual patient's tumour. To support this mission Evotec will provide its full range of discovery and oncology services, through its discovery and pre-clinical platform. Carrick will progress multiple programmes through hit-to-lead and lead optimisation with the goal of delivering multiple development candidates. Dr Werner Lanthaler, Chief Executive Officer of Evotec commented: "We are very excited to be part of creating and co-owning a next generation leading oncology company. Putting all Evotec's tools that support innovation and capital efficiency at work will allow Carrick to very rapidly progress a first-in-class oncology pipeline." Chief Executive of Carrick Therapeutics, Dr Elaine Sullivan, said: "This is a unique new venture in cancer treatment, backed by some of the highest quality investors in the field. There is a significant unmet need in cancer treatment, and targeting aggressive and resistant disease is an area where we can make a real difference to patients' lives. Working with Evotec has allowed us to build a pipeline with optimal speed and highest quality." No further financial details are disclosed. Evotec's financial guidance for 2016, also with regard to liquidity, remains unchanged, despite the recent investment in Topas Therapeutics and now Carrick Therapeutics. ABOUT CARRICK THERAPEUTICS Carrick Therapeutics is pioneering a portfolio of unique, first in class, cancer treatments that target driver mechanisms of the most aggressive forms of cancer, and which will be tailored to an individual patient's tumour. The name Carrick means 'rock' in Irish to emphasise the strong foundation of like-minded scientists, collaborators and investors, and the vision to build a durable world-class company. Carrick has an ambitious patient focussed vision to serve cancer patients around the world by the introduction of ground breaking cancer therapies that will transform the way cancer is treated. ABOUT EVOTEC AG Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 70 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and development partnerships with e.g. Janssen Pharmaceuticals in the field of Alzheimer's disease, with Sanofi in the field of diabetes and with Pfizer in the field of tissue fibrosis. For additional information please go to www.evotec.com. FORWARD LOOKING STATEMENTS Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based. Contact Evotec AG: Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone: +49.(0)40.56081-255, [email protected] --------------------------------------------------------------------------- 04.10.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: Evotec AG Manfred Eigen Campus / Essener Bogen 7 22419 Hamburg Germany Phone: +49 (0)40 560 81-0 Fax: +49 (0)40 560 81-222 E-mail: [email protected] Internet: www.evotec.com ISIN: DE0005664809 WKN: 566480 Indices: TecDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange End of News DGAP News Service --------------------------------------------------------------------------- 508341 04.10.2016


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 257,63 375,41 446,44 500,92 618,03 751,45 835,00
EBITDA1,2 57,22 95,46 123,14 51,77 101,65 102,51 122,00
EBITDA-Marge3 22,21 25,43 27,58 10,33 16,45 13,64
EBIT1,4 37,50 77,46 62,59 48,52 41,00 20,85 0,00
EBIT-Marge5 14,56 20,63 14,02 9,69 6,63 2,78 0,00
Jahresüberschuss1 24,00 84,06 37,23 6,25 215,51 -175,66 0,00
Netto-Marge6 9,32 22,39 8,34 1,25 34,87 -23,38 0,00
Cashflow1,7 10,83 156,24 42,22 44,72 122,24 203,11 0,00
Ergebnis je Aktie8 0,16 0,46 0,25 0,04 1,30 -0,99 -0,50
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2022 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: BDO

INVESTOR-INFORMATIONEN
©boersengefluester.de
Evotec
WKN Kurs in € Einschätzung Börsenwert in Mio. €
566480 14,470 Halten 2.569,03
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
21,28 35,54 0,60 81,75
KBV KCV KUV EV/EBITDA
2,25 12,65 3,42 25,93
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,00 0,00 0,00 10.06.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
22.05.2024 14.08.2024 08.11.2023 24.04.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
1,48% -20,70% -32,00% -24,26%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Evotec AG  ISIN: DE0005664809 können Sie bei EQS abrufen


Biotechnologie , 566480 , EVT , XETR:EVT